EU Countries Examine Reasons Behind Wide Differences In Biosimilar Usage

 
• By Ian Schofield
  
Generate a summary of this article
Listen to this article
Beta

Speakers from several EU countries at last week's Medicines for Europe conference discussed the reasons behind the often wide inter-country disparities in biosimilar usage and the policies they are pursuing to try to remedy the situation.

Biosimilars
Biosimilar uptake and policies vary by country and by product • Source: Shutterstock

It’s no secret that while biosimilar medicines are gradually consolidating their presence in the Europe pharmaceutical market, their use varies widely by molecule and by country, and often within the same country, depending on factors such as doctor incentives, purchasing and reimbursement policies, and the perceptions of healthcare professionals and patients that are often swayed by misinformation on the safety of biosimilars.

Speakers from several European countries outlined their experiences with biosimilars to date at Medicines For Europe’s 17th biosimilars conference, which...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.